| Assay ID | Title | Year | Journal | Article |
|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1467530 | Inhibition of Streptococcus pneumoniae sialidase NanA using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by FRET assay | 2017 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
| Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans. |
| AID1467531 | Noncompetitive inhibition of Streptococcus pneumoniae sialidase NanA using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by Lineweaver-Burk plot/Dixon plot analysis | 2017 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
| Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans. |
| AID443489 | Inhibition of ovine COX-1 assessed as inhibition of transformation of AA to PGH2 by EIA | 2009 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
| COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. |
| AID398796 | Cytotoxicity against human KB cells | | | |
| AID443495 | Antiplatelet activity in rabbit platelets assessed as inhibition of adenosin 5'-diphosphate-induced platelet aggregation | 2009 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
| COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. |
| AID1741961 | Selectivity index, ratio of IC50 for cytotoxicity against rat L6 cells to IC50 for antileishmanial activity against Leishmania donovani MHOM/ET/67/L82 amastigotes | 2020 | European journal of medicinal chemistry, Nov-01, Volume: 205 | (±)-trans-2-phenyl-2,3-dihydrobenzofurans as leishmanicidal agents: Synthesis, in vitro evaluation and SAR analysis. |
| AID1741960 | Cytotoxicity against rat L6 cells assessed as reduction in cell viability incubated for 70 hrs by resazurin staining based inverted microscopic analysis | 2020 | European journal of medicinal chemistry, Nov-01, Volume: 205 | (±)-trans-2-phenyl-2,3-dihydrobenzofurans as leishmanicidal agents: Synthesis, in vitro evaluation and SAR analysis. |
| AID1467529 | Inhibition of Streptococcus pneumoniae sialidase NanB using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by FRET assay | 2017 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
| Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans. |
| AID443491 | Inhibition of potato LOX-5 assessed as inhibition of hydroperoxide production after 5 mins by EIA | 2009 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
| COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. |
| AID612672 | Inhibition of rabbit muscle glycogen phosphorylase 1a assessed as release of phosphate from glucose-1- phosphate at 10 uM after 20 mins | 2011 | Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
| Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leads. |
| AID1467533 | Inhibition of Streptococcus pneumoniae sialidase NanC using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by FRET assay | 2017 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
| Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans. |
| AID443490 | Inhibition of ovine COX-2 assessed as inhibition of transformation of AA to PGH2 by EIA | 2009 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
| COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. |
| AID612673 | Inhibition of rabbit muscle glycogen phosphorylase 1a assessed as release of phosphate from glucose-1- phosphate after 20 mins | 2011 | Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
| Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leads. |
| AID1741959 | Antileishmanial activity against Leishmania donovani MHOM/ET/67/L82 amastigotes assessed as growth inhibition incubated for 70 hrs by resazurin based inverted microscopic analysis | 2020 | European journal of medicinal chemistry, Nov-01, Volume: 205 | (±)-trans-2-phenyl-2,3-dihydrobenzofurans as leishmanicidal agents: Synthesis, in vitro evaluation and SAR analysis. |
| AID1064256 | Prothrombotic activity in New Zealand white rabbit platelets assessed as increase in platelet aggregation at 100 uM by spectrophotometry | 2014 | Journal of natural products, Jan-24, Volume: 77, Issue:1
| Lignans from the aerial parts of Saururus chinensis: isolation, structural characterization, and their effects on platelet aggregation. |
| AID443493 | Antiplatelet activity in rabbit platelets assessed as inhibition of platelet activating factor-induced platelet aggregation | 2009 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
| COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. |
| AID443494 | Antiplatelet activity in rabbit platelets assessed as inhibition of arachidonic acid-induced platelet aggregation | 2009 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
| COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. |
| AID443492 | Selectivity ratio of IC50 for ovine COX-1 to IC50 for ovine COX-2 | 2009 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
| COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |